Suchergebnisse - "Cao, Bin"

PubPharm (121)

71

Dynamics of the upper respiratory tract microbiota and its association with fatality in COVID-19 patients

enthalten in: ResearchSquare.com | 2021

von Li, M. | Ren, L. | Wang, Y. | +26

72

Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2021

von Yahav, D. | Yelin, D. | Eckerle, I. | +4

73

Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study

enthalten in: bioRxiv.org | 2021

von Liu, C. | Wang, Q. | Wang, Y. | +13

74

6-month consequences of COVID-19 in patients discharged from hospital : a cohort study

enthalten in: Lancet (London, England) | 2021

von Huang, C. | Huang, L. | Wang, Y. | +29

CommentIn: Lancet. 2021 Jan 16;397(10270):173-175. - PMID 33428868

75

Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2021

von Liu, Z. | Li, X. | Fan, G. | +15

76

Presence of Anti-MDA5 Antibody and Its Value for the Clinical Assessment in Patients With COVID-19 : A Retrospective Cohort Study

enthalten in: Frontiers in immunology | 2021

von Wang, G. | Wang, Q. | Wang, Y. | +14

77

The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19 : A Living Systematic Review and Meta-Analysis

enthalten in: Frontiers in medicine | 2021

von Zhang, X. | Shang, L. | Fan, G. | +5

CommentIn: Dig Liver Dis. 2022 Nov;54(11):1598-1599. - PMID 36137935

78

Letter from China : Managing the second‐wave COVID‐19 outbreak in Beijing

enthalten in: Respirology | 2021

von Xu, J. | Cao, B.

79

Contemporary narrative review of treatment options for COVID‐19

enthalten in: Respirology | 2021

von Shang, L. | Lye, D. | Cao, B.

80

Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza

enthalten in: EBioMedicine | 2020

von Wang, Y. | Zhong, W. | Salam, A. | +29